Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: final analysis of a phase II trial

Axel Glasmacher; Hartmut Goldschmidt; Jörg Mezger; Torsten Haferlach; Ingo G H Schmidt-Wolf; Frank Gieseler; Phase II trial

Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: final analysis of a phase II trial

Haematologica. 2004 Mar;89(3):371-3.

Authors

Axel Glasmacher, Hartmut Goldschmidt, Jörg Mezger, Torsten Haferlach, Ingo G H Schmidt-Wolf, Frank Gieseler; Phase II trial

PMID: 15020285

Abstract

This prospective phase II study evaluated a regimen with vincristine, oral idarubicin and dexamethasone (VID) in 74 patients with multiple myeloma. A partial response was achieved in 57% (16/28) of patients with previously untreated disease and in 35% (16/46) with refractory diseases. VID chemotherapy is an effective and tolerable oral alternative in an outpatient setting for these patients.

Publication types

Clinical Trial, Phase II
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Dexamethasone / administration & dosage
Female
Humans
Idarubicin / administration & dosage
Male
Middle Aged
Multiple Myeloma / drug therapy*
Prospective Studies
Vincristine / administration & dosage

Substances

Vincristine
Dexamethasone
Idarubicin